Daria Eygel

Ms. Daria Eygel

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
Ilya D. KlabukovIlya D. Klabukov
Ilya D. Klabukov
AKAlexander E. Kabakov
Alexander E. Kabakov
AYAnna Yakimova
Anna Yakimova
DBDenis Baranovskii
Denis Baranovskii
DSDmitry Vitalievich Sosin
Dmitry Vitalievich Sosin
AKAndrei Kaprin
Andrei Kaprin
Chimeric antigen receptor (CAR)-T cell therapy yields good results in the treatment of various hematologic malignancies. However, the efficacy of CAR-T cell therapy against solid tumors has proven to be limited, primarily because the tumor-associated extracellular matrix (ECM) creates an intractable barrier for the cytotoxic CAR-T cells that are supposed to kill cancer cells. This review unravels the multifaceted role of the tumor-associated ECM in impeding CAR-T cell infiltration, survival, and functions within solid tumors. We analyze the situations when intratumoral ECM limits the efficacy of CAR-T cell therapy by being a purely physical barrier that complicates lymphocyte penetration/migration and also acts as an immunosuppressive factor that impairs the antitumor activities of CAR-T cells. In addition, we highlight promising approaches such as engineering CAR-T cells with improved capabilities to penetrate and migrate into/through the intratumoral ECM, combination therapies aimed at attenuating the high density and immunosuppressive potential of the intratumoral ECM, and others that enable overcoming ECM-related obstacles. A detailed overview of the data of relevant studies not only helps to better understand the interactions between CAR-T cells and the intratumoral ECM but also outlines potential ways to more effectively use CAR-T cell therapy against solid tumors.

Verified
Journal Article
Open access
PDF file
Ilya D. KlabukovIlya D. Klabukov
Ilya D. Klabukov
DEDaria Eygel
Daria Eygel
EIElena Isaeva
Elena Isaeva
AKAnastas Kisel
Anastas Kisel
EIEvgeny I. Isaev
Evgeny I. Isaev
AKAndrei Kaprin
Andrei Kaprin
Non-ionizing radiation and excited states can modify the properties of biological tissues, altering their structure, surface morphology and mechanical properties of the extracellular matrix, and stimulating resident cells. The primary goal of non-ionizing radiation applications is to achieve high precision and controllability in the processes of modifying biological tissues, allowing for the minimization of damage to surrounding healthy tissues and improving repair processes. The use of the photonic and acoustic methods can contribute to the creation of new materials with specific biological properties, which is particularly important for the development of individualized implants, efficient drug delivery systems, and tissue engineering methods. An important aspect is the development of integrated approaches that combine different types of non-ionizing radiation to achieve a synergistic effect we term a “bosonic concentrate.” For example, the combination of photonic and phononic ultrasonic therapy can improve the penetration of drugs into deeper tissue layers, while the combination of photothermal and acoustic exposure can increase the precision and efficiency of tumor cell removal. This review discusses the effects underlying the potential treatment options for biological tissue modification to improve their physiological relevance based on various bosonic concentrate combinations. In particular, we will discuss how low-energy acoustic phonons (characteristic energy 0.03–0.1 eV) could create tissue-specific spatially resolved structures that serve as matrices for optical photons (1–3 eV) and excitons (~0.1 eV) and how they could be focused and dissipated to mediate biochemical reactions. All of them are capable of propagating in living tissues, mediating changes at the cellular and molecular levels.